Clinical Genomics

Clinical Genomics

Edited by  , Edited by 

List price: US$150.00

Currently unavailable

We can notify you when this item is back in stock

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks


Clinical Genomics provides an overview of the various next-generation sequencing (NGS) technologies that are currently used in clinical diagnostic laboratories. It presents key bioinformatic challenges and the solutions that must be addressed by clinical genomicists and genomic pathologists, such as specific pipelines for identification of the full range of variants that are clinically important. This book is also focused on the challenges of diagnostic interpretation of NGS results in a clinical setting. Its final sections are devoted to the emerging regulatory issues that will govern clinical use of NGS, and reimbursement paradigms that will affect the way in which laboratory professionals get paid for the testing. * Simplifies complexities of NGS technologies for rapid education of clinical genomicists and genomic pathologists towards genomic medicine paradigm* Tried and tested practice-based analysis for precision diagnosis and treatment plans* Specific pipelines and meta-analysis for full range of clinically important variants
show more

Product details

  • Electronic book text | 488 pages
  • 216 x 276mm
  • Academic Press Inc
  • San Diego, United States
  • English
  • 0124051731
  • 9780124051737

About Shashikant Kulkarni

Dr. Shashikant Kulkarni is the Head of Clinical Genomics, Genomics and Pathology Services and also the Director of Cytogenomics and Molecular Pathology at Washington University School of Medicine. In addition, he is Associate Professor of Pathology and Immunology, Pediatrics, and Genetics. His lab's principle research interest is delineation of novel genomic structural and single nucleotide variants in cancer.
show more

Table of contents

Section 1: Methods

Overview of technical aspects and chemistries of NGS: Dr Robi Mitra, Washington University School of Medicine. Non-selective methods (genome-wide): Dr Mark Bogoski, Harvard Medical School Capture based methods (exome, panels) Dr Birgit Funke, Harvard Medical School Amplification based methods (panels): Dr Madhuri Hegde, Emory Medical School Emerging technologies (Nanopore and others); impact on cost and turnaround time: Dr Elaine Mardis, Washington University School of Medicine. Section 2: Bioinformatics

Base calling and alignment; quality metrics; depth of coverage: Dr Carl Volkerding, University of Utah, ARUP labs Single nucleotide variants (SNVs): Dr David Spencer, Washington University School of Medicine Insertions and deletions (Indels): Drs Eric Duncavage and Haley Abel, Washington University School of Medicine Large structural alterations (big deletions, translocations, and so on): Dr Charles Mullighan, St Jude's Cancer Institute Copy number variants (CNVs): Dr Mary-Claire King, University of Washington Section 3: Interpretation

Reference data bases for disease associations: Dr Heidi Rehm, Harvard Medical School Reporting of results; level of evidence for associations; classes of associations: Dr Shashikant Kulkarni, Washington University School of Medicine Constitutional diseases (with individual chapters on hypertrophic cardiomyopathy, congenital deafness, blindness, cancer syndromes, and so on): Dr David Bick and Dr David Dimmock, Medical College of Wisconsin Cancer (with individual chapters on leukemia, lymphoma, lung cancer, colon cancer, and so on): Dr John Pfeifer, Washington University School of Medicine Section 4: Regulatory Issues

Assay validation: Dr Ira Lublin, CDC and Dr Elizabeth Mansfield FDA QA/QC/PT issues: Dr Elaine Lyon, University of Utah, ARUP labs Consent and privacy issues: Dr James DuBois, Albert Gnaegi Center for Health Care Ethics Section 5: Reimbursement

Billing: Andrew Drury and Kris Rickoff, Washington University School of Medicine
show more